Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy
Karrune Woan(University of Minnesota), Frank Cichocki(University of Minnesota), Miguel Meza(Fate Therapeutics (United States)), Ryan Bjordahl(Fate Therapeutics (United States)), Yenan T. Bryceson(Karolinska University Hospital), Bruce Walcheck(University of Veterinary Science), Jeffrey S. Miller(Palmetto Hematology Oncology), John Goulding(Fate Therapeutics (United States)), Greg Bonello(Fate Therapeutics (United States)), Cheng‐Ying Wu(University of Minnesota), Martin Felices(University of Minnesota), Behiye Kodal(University of Minnesota), Svetlana Gaidarova(Fate Therapeutics (United States)), Ramzey Abujarour(Fate Therapeutics (United States)), Bruce R. Blazar(Unknown), Karl‐Johan Malmberg(Karolinska University Hospital), Paul Rogers(Fate Therapeutics (United States)), Zachary Davis(University of Minnesota), Bahram Valamehr(Fate Therapeutics (United States)), Melissa Khaw(University of Minnesota), Laura E. Bendzick(University of Minnesota), Brian Hancock(Fate Therapeutics (United States)), Janel Huffman(Fate Therapeutics (United States)), Tom T. Lee(Fate Therapeutics (United States)), Sajid Mahmood(University of Management and Technology), Bin Zhang(Palmetto Hematology Oncology), Hongbo Wang(University of Minnesota), Hansol Kim(University of Minnesota), Moyar Ge(Fate Therapeutics (United States)), Thomas Dailey(Fate Therapeutics (United States)), Katie Tuininga(University of Minnesota)
Cited by 153
Related Papers
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
|Blood|2013|537
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
|Blood|2018|406
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
|Journal of Clinical Investigation|2017|311